UK Regulator Reports 150,000 Adverse Events and 153 Deaths Linked to Weight-Loss Jabs
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Liraglutide
DrugDrug Profile
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in type 2 diabetes and obesity-related treatment pathways under brands such as Victoza and Saxenda. It is used for glycemic control and cardiovascular risk reduction in appropriate diabetes populations, and is also used for chronic weight management in obesity/overweight indications. U.S. FDA approval history for Victoza begins in 2010.
- Drug Class
- GLP-1 receptor agonist
- Approval Status
- FDA approved (Victoza); first approved January 25, 2010.
- Mechanism of Action
- Glucagon-like peptide-1 (GLP-1) receptor agonism.
- Victoza
- Saxenda
- \Type 2 diabetes\
- \Cardiovascular risk reduction\
- \Weight loss (obesity/overweight)\
Related News
Semaglutide Linked to Lower Seizure and Alcohol-Related Hospitalization Risks; Brazil Approves Five New GLP-1 Drugs
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
GLP-1 Drugs: Smell and Taste Risks, Soaring Poison Calls, and Reshaped Food Demand
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
FDA Proposes Limits on Compounding for GLP-1 Drugs as Safety Fears Grow
The FDA proposes to remove three GLP-1 drugs from the bulk compounding list as adverse events near 2,000 and Senator Tom Cotton demands a probe into Chinese APIs in compounded meds. Shortages have largely resolved, but safety and innovation concerns persist.
FDA Restricts Compounded GLP-1 Drugs as Weight-Loss Pill Race Heats Up
The FDA moved to exclude semaglutide, tirzepatide and liraglutide from its 503B compounding list. Eli Lilly won U.S. approval for its oral pill Foundayo, and Novo Nordisk sued Lilly over allegedly misleading weight-loss ads.
FDA Recalls Generic Adderall XR, Levothyroxine, Gas-X, and Moringa Supplements
Nationwide FDA recalls include generic Adderall XR (mix-up), levothyroxine (subpotent), Gas-X (coolant contamination), and several prescription drugs classed as Class II. Moringa dietary supplements are under Class I recall due to serious health risks. Consumers are advised to check lot numbers and consult pharmacists.
Active pharmaceutical ingredients market seen reaching $198.39 billion by 2030
The global API market is projected to grow to USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a 6.6% CAGR. Oncology, rare disease and diabetes pipelines are key growth drivers.
Studies Support Combined SGLT2 Inhibitor and GLP-1 Therapy for Type 2 Diabetes Management
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
GLP-1 Drugs Show Broader Effects Through Gene Expression and Gut Microbiome Interactions
New research reveals how GLP-1 receptor agonists promote pancreatic health through gene expression changes and interact bidirectionally with gut microbiome, while real-world users report unexpected lifestyle changes alongside weight loss.
GLP-1 Medications Reduce Risk of Substance Use Disorders and Overdose Deaths, Study Finds
A large study of over 600,000 U.S. veterans with type 2 diabetes found GLP-1 medications reduced the risk of developing substance use disorders by 14% and cut drug-related deaths by 50% in those with existing addiction.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07244003 |
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control |
RECRUITING | PHASE4 |
| NCT07225816 |
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) |
RECRUITING | PHASE1 |
| NCT07029009 |
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY) |
RECRUITING | PHASE2 |
| NCT06818292 |
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists |
COMPLETED | NA |
| NCT06501326 |
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease |
RECRUITING | PHASE4 |
| NCT06438146 |
LIROH - Liraglutide for Obesity in HIV |
RECRUITING | PHASE4 |
| NCT06283641 |
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. |
COMPLETED | |
| NCT06099067 |
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP) |
COMPLETED | |
| NCT05965908 |
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome |
COMPLETED | PHASE3 |
| NCT05779644 |
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus |
UNKNOWN | NA |